Literature DB >> 29073947

Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.

Robert W Yeh1, Dean J Kereiakes2, P Gabriel Steg3, Donald E Cutlip4, Kevin J Croce5, Joseph M Massaro6, Laura Mauri7.   

Abstract

BACKGROUND: Subjects undergoing coronary stenting with complex lesion anatomy may experience different risks and benefits with prolonged dual antiplatelet therapy.
OBJECTIVES: The authors assessed the effect of 30 months versus 12 months of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) based on the presence or absence of anatomically-complex target lesions.
METHODS: In the DAPT Study, combined myocardial infarction (MI) or stent thrombosis and moderate/severe bleeding were assessed in enrolled (n = 25,416) and randomized (n = 11,554) subjects. Complex lesions had any of the following characteristics: unprotected left main, >2 lesions/vessel, length ≥30 mm, bifurcation with side branch ≥2.5 mm, vein bypass graft, or thrombus-containing lesion. Events were evaluated according to increasing number of complexity characteristics and compared according to DAPT score.
RESULTS: Enrolled subjects with more complex target lesions had higher rates of MI or stent thrombosis in the first 12 months after PCI (3.9% vs. 2.4%; p < 0.001). Among those who were event-free at 12 months, rates of MI or stent thrombosis between 12 and 30 months were similar between those with versus without complex anatomy (3.5% vs. 2.9%; p = 0.07). Reduction of MI or stent thrombosis with continued thienopyridine beyond 12 months versus placebo was similar for subjects with (2.5% vs. 4.5%; hazard ratio: 0.55; 95% confidence interval: 0.38 to 0.79; p = 0.001) and without (2.0% vs. 3.8%; hazard ratio: 0.52; 95% confidence interval: 0.39 to 0.69; p < 0.001) anatomic complexity (pinteraction = 0.81), as was increase in moderate/severe bleeding (pinteraction = 0.44). Among subjects with anatomic complexity, those with DAPT scores ≥2 randomized to continued thienopyridine had greater reductions in MI or stent thrombosis (3.0% vs. 6.1%; p < 0.001) compared with subjects with scores <2 (1.7% vs. 2.3%; p = 0.42; p value comparing risk differences = 0.03).
CONCLUSIONS: Complex target-lesion anatomy is associated with increased ischemic events, particularly within the first year after PCI. Among those without events in the first 12 months, the benefits of extending DAPT were similar in subjects with and without complex lesions. A high DAPT score identified those experiencing the most benefit from extended treatment among patients with and without complex anatomy. (The Dual Antiplatelet Therapy Study [DAPT Study]; NCT00977938).
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  complex lesions; dual antiplatelet therapy; dual antiplatelet therapy score; percutaneous coronary intervention

Mesh:

Substances:

Year:  2017        PMID: 29073947      PMCID: PMC7754792          DOI: 10.1016/j.jacc.2017.09.011

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Authors:  Laura Mauri; Dean J Kereiakes; Robert W Yeh; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Sharon-Lise T Normand; Eugene Braunwald; Stephen D Wiviott; David J Cohen; David R Holmes; Mitchell W Krucoff; James Hermiller; Harold L Dauerman; Daniel I Simon; David E Kandzari; Kirk N Garratt; David P Lee; Thomas K Pow; Peter Ver Lee; Michael J Rinaldi; Joseph M Massaro
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Clinical end points in coronary stent trials: a case for standardized definitions.

Authors:  Donald E Cutlip; Stephan Windecker; Roxana Mehran; Ashley Boam; David J Cohen; Gerrit-Anne van Es; P Gabriel Steg; Marie-angèle Morel; Laura Mauri; Pascal Vranckx; Eugene McFadden; Alexandra Lansky; Martial Hamon; Mitchell W Krucoff; Patrick W Serruys
Journal:  Circulation       Date:  2007-05-01       Impact factor: 29.690

3.  Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.

Authors:  Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White
Journal:  Circulation       Date:  2011-06-14       Impact factor: 29.690

4.  Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.

Authors:  Dean J Kereiakes; Robert W Yeh; Joseph M Massaro; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Anthony H Gershlick; Harald Darius; Ian T Meredith; John Ormiston; Jean Francois Tanguay; Stephan Windecker; Kirk N Garratt; David E Kandzari; David P Lee; Daniel I Simon; Adrian Corneliu Iancu; Jaroslaw Trebacz; Laura Mauri
Journal:  JAMA       Date:  2015-03-17       Impact factor: 56.272

5.  Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI.

Authors:  Gennaro Giustino; Alaide Chieffo; Tullio Palmerini; Marco Valgimigli; Fausto Feres; Alexandre Abizaid; Ricardo A Costa; Myeong-Ki Hong; Byeong-Keuk Kim; Yangsoo Jang; Hyo-Soo Kim; Kyung Woo Park; Martine Gilard; Marie-Claude Morice; Fadi Sawaya; Gennaro Sardella; Philippe Genereux; Bjorn Redfors; Martin B Leon; Deepak L Bhatt; Gregg W Stone; Antonio Colombo
Journal:  J Am Coll Cardiol       Date:  2016-08-29       Impact factor: 24.094

6.  Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.

Authors:  Laura Mauri; Dean J Kereiakes; Sharon-Lise T Normand; Stephen D Wiviott; David J Cohen; David R Holmes; Sripal Bangalore; Donald E Cutlip; Michael Pencina; Joseph M Massaro
Journal:  Am Heart J       Date:  2010-12       Impact factor: 4.749

7.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-02       Impact factor: 91.245

8.  Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study.

Authors:  Ian T Meredith; Jean-François Tanguay; Dean J Kereiakes; Donald E Cutlip; Robert W Yeh; Kirk N Garratt; David P Lee; P Gabriel Steg; W Douglas Weaver; David R Holmes; Ralph G Brindis; Jaroslaw Trebacz; Joseph M Massaro; Wen-Hua Hsieh; Laura Mauri
Journal:  Circulation       Date:  2016-03-18       Impact factor: 29.690

9.  Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.

Authors:  James B Hermiller; Mitchell W Krucoff; Dean J Kereiakes; Stephan Windecker; P Gabriel Steg; Robert W Yeh; David J Cohen; Donald E Cutlip; Joseph M Massaro; Wen-Hua Hsieh; Laura Mauri
Journal:  JACC Cardiovasc Interv       Date:  2016-01-25       Impact factor: 11.195

10.  DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction.

Authors:  Dean J Kereiakes; Robert W Yeh; Joseph M Massaro; Donald E Cutlip; P Gabriel Steg; Stephen D Wiviott; Laura Mauri
Journal:  J Am Coll Cardiol       Date:  2016-04-01       Impact factor: 24.094

View more
  15 in total

Review 1.  Coronary Stent Thrombosis- Predictors and Prevention.

Authors:  Helen Ullrich; Thomas Münzel; Tommaso Gori
Journal:  Dtsch Arztebl Int       Date:  2020-05-01       Impact factor: 5.594

Review 2.  Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management.

Authors:  Davide Cao; Rishi Chandiramani; Davide Capodanno; Jeffrey S Berger; Matthew A Levin; Mary T Hawn; Dominick J Angiolillo; Roxana Mehran
Journal:  Nat Rev Cardiol       Date:  2020-08-05       Impact factor: 32.419

Review 3.  Complex PCI procedures: challenges for the interventional cardiologist.

Authors:  Nikos Werner; Georg Nickenig; Jan-Malte Sinning
Journal:  Clin Res Cardiol       Date:  2018-07-05       Impact factor: 5.460

4.  Prognostic and Practical Validation of ESC/EACTS High Ischemic Risk Definition on Long-Term Thrombotic and Bleeding Events in Contemporary PCI Patients.

Authors:  Hao-Yu Wang; Dong Yin; Yan-Yan Zhao; Rui Zhang; Yue-Jin Yang; Bo Xu; Ke-Fei Dou
Journal:  J Atheroscler Thromb       Date:  2021-03-20       Impact factor: 4.394

5.  Five-year clinical follow-up of the STENTYS self-apposing stent in complex coronary anatomy: a single-centre experience with report of specific angiographic indications.

Authors:  H Lu; R J Bekker; M J Grundeken; P Woudstra; J J Wykrzykowska; J G P Tijssen; R J de Winter; K T Koch
Journal:  Neth Heart J       Date:  2018-05       Impact factor: 2.380

6.  Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI.

Authors:  Hao-Yu Wang; Ke-Fei Dou; Dong Yin; Dong Zhang; Run-Lin Gao; Yue-Jin Yang
Journal:  BMC Cardiovasc Disord       Date:  2020-07-01       Impact factor: 2.298

7.  Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.

Authors:  Jonas Oldgren; Philippe Gabriel Steg; Stefan H Hohnloser; Gregory Y H Lip; Takeshi Kimura; Matias Nordaby; Martina Brueckmann; Eva Kleine; Jurrien M Ten Berg; Deepak L Bhatt; Christopher P Cannon
Journal:  Eur Heart J       Date:  2019-05-14       Impact factor: 29.983

8.  Percutaneous Coronary Intervention Complexity and Risk of Adverse Events in relation to High Bleeding Risk among Patients Receiving Drug-Eluting Stents: Insights from a Large Single-Center Cohort Study.

Authors:  Hao-Yu Wang; Yang Wang; Dong Yin; Run-Lin Gao; Yue-Jin Yang; Bo Xu; Ke-Fei Dou
Journal:  J Interv Cardiol       Date:  2020-04-25       Impact factor: 2.279

Review 9.  Optimal duration of dual antiplatelet therapy for coronary artery disease.

Authors:  W J Kikkert; P Damman
Journal:  Neth Heart J       Date:  2018-06       Impact factor: 2.380

10.  Contradictions between DAPT and PRECISE-DAPT scores with the severity of coronary lesion in acute coronary syndrome.

Authors:  Sisi Bi; Yue Zhao; Qingling Peng; Wenxue Liu; Guogang Zhang; Chenglong Zhang
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.